Literature DB >> 9143294

Antigenic variants of yellow fever virus with an altered neurovirulence phenotype in mice.

K D Ryman1, H Xie, T N Ledger, G A Campbell, A D Barrett.   

Abstract

The live-attenuated yellow fever (YF) vaccine virus, strain 17D-204, has long been known to consist of a heterologous population of virions. Gould et al. (J. Gen. Virol. 70, 1889-1894 (1989)) previously demonstrated that variant viruses exhibiting a YF wild-type-specific envelope (E) protein epitope are present at low frequency in the vaccine pool and were able to isolate representative virus variants with and without this epitope, designated 17D(+wt) and 17D(-wt), respectively. These variants were employed here in an investigation of YF virus pathogenesis in the mouse model. Both the 17D-204 parent and the 17D(+wt) variant viruses were lethal for adult outbred mice by the intracerebral route of inoculation. However, the 17D(-wt) variant was significantly attenuated (18% mortality rate) and replicated to much lower titer in the brains of infected mice. A single amino acid substitution in the envelope (E) protein at E-240 (Ala-->Val) was identified as responsible for the restricted replication of the 17D(-wt) variant in vivo. The 17D(+wt) variant has an additional second-site mutation, believed to encode a reversion to the neurovirulence phenotype of the 17D-204 parent virus. The amino acid substitution in the E protein at E-173 (Thr-->Ile) of the 17D(+wt) variant which results in the appearance of the wild-type-specific epitope or nucleotide changes in the 5' and 3' noncoding regions of the virus are proposed as a candidates.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9143294     DOI: 10.1006/viro.1997.8496

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  15 in total

Review 1.  Perspectives for the treatment of infections with Flaviviridae.

Authors:  P Leyssen; E De Clercq; J Neyts
Journal:  Clin Microbiol Rev       Date:  2000-01       Impact factor: 26.132

Review 2.  Learning immunology from the yellow fever vaccine: innate immunity to systems vaccinology.

Authors:  Bali Pulendran
Journal:  Nat Rev Immunol       Date:  2009-09-18       Impact factor: 53.106

3.  Comparison of the neurovirulence of a vaccine and a wild-type mumps virus strain in the developing rat brain.

Authors:  S A Rubin; M Pletnikov; K M Carbone
Journal:  J Virol       Date:  1998-10       Impact factor: 5.103

4.  ChimeriVax-West Nile virus live-attenuated vaccine: preclinical evaluation of safety, immunogenicity, and efficacy.

Authors:  Juan Arroyo; Chuck Miller; John Catalan; Gwendolyn A Myers; Marion S Ratterree; Dennis W Trent; Thomas P Monath
Journal:  J Virol       Date:  2004-11       Impact factor: 5.103

5.  Neuroadapted yellow fever virus 17D: genetic and biological characterization of a highly mouse-neurovirulent virus and its infectious molecular clone.

Authors:  T J Chambers; M Nickells
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

6.  Advanced age a risk factor for illness temporally associated with yellow fever vaccination.

Authors:  M Martin; L H Weld; T F Tsai; G T Mootrey; R T Chen; M Niu; M S Cetron
Journal:  Emerg Infect Dis       Date:  2001 Nov-Dec       Impact factor: 6.883

7.  E protein domain III determinants of yellow fever virus 17D vaccine strain enhance binding to glycosaminoglycans, impede virus spread, and attenuate virulence.

Authors:  Eva Lee; Mario Lobigs
Journal:  J Virol       Date:  2008-04-09       Impact factor: 5.103

8.  Humanized monoclonal antibodies derived from chimpanzee Fabs protect against Japanese encephalitis virus in vitro and in vivo.

Authors:  Ana P Goncalvez; Cheng-Hsin Chien; Kamolchanok Tubthong; Inna Gorshkova; Carrie Roll; Olivia Donau; Peter Schuck; Sutee Yoksan; Sy-Dar Wang; Robert H Purcell; Ching-Juh Lai
Journal:  J Virol       Date:  2008-05-14       Impact factor: 5.103

9.  Neuroadapted yellow fever virus strain 17D: a charged locus in domain III of the E protein governs heparin binding activity and neuroinvasiveness in the SCID mouse model.

Authors:  Janice Nickells; Maria Cannella; Deborah A Droll; Yan Liang; William S M Wold; Thomas J Chambers
Journal:  J Virol       Date:  2008-10-08       Impact factor: 5.103

10.  A mouse model for studying viscerotropic disease caused by yellow fever virus infection.

Authors:  Kathryn C Meier; Christina L Gardner; Mikhail V Khoretonenko; William B Klimstra; Kate D Ryman
Journal:  PLoS Pathog       Date:  2009-10-09       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.